Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Published Online
on February 4, 2008

Hypertension. 2008
Published online before print February 4, 2008, doi: 10.1161/HYPERTENSIONAHA.107.104901
A more recent version of this article appeared on March 1, 2008
This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
51/3/749    most recent
HYPERTENSIONAHA.107.104901v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Iwazu, Y.
Right arrow Articles by Kusano, E.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Iwazu, Y.
Right arrow Articles by Kusano, E.
Related Collections
Right arrow Angiogenesis
Right arrow Animal models of human disease
Right arrow Apoptosis

Submitted on November 12, 2007
Revised on December 10, 2007

Spironolactone Suppresses Peritubular Capillary Loss and Prevents Deoxycorticosterone Acetate/Salt-Induced Tubulointerstitial Fibrosis

Yoshitaka Iwazu; Shigeaki Muto*; Genro Fujisawa; Eiko Nakazawa; Koji Okada; Shun Ishibashi; and Eiji Kusano

From the Departments of Nephrology (Y.I., S.M., E.N., E.K.), and Endocrinology and Metabolism (G.F., K.O., S.I.), Jichi Medical University, Tochigi, Japan.

* To whom correspondence should be addressed. E-mail: smuto{at}jichi.ac.jp.

Abstract—We examined whether and how peritubular capillary (PTC) loss in the renal cortex contributes to the development of deoxycorticosterone acetate (DOCA)/salt-induced tubulointerstitial fibrosis. Uninephrectomized rats provided with 0.9% NaCl/0.3% KCl drinking solution ad libitum were divided into control, DOCA, and spironolactone groups, which were administered vehicle, DOCA alone, and DOCA plus spironolactone for 1 (initial phase) and 4 weeks (delayed phase), respectively. Exposure to DOCA initiated a sequence of events that initially involved reduced PTC density, followed by a delayed response that involved further reduced PTC density, development of tubulointerstitial fibrosis and hypertension, enhanced expression of transforming growth factor-{beta}1 and connective tissue growth factor, and impaired renal function. Concomitant with the reduced PTC density, the 2 hypoxia-responsive angiogenic factors (vascular endothelial growth factor and hypoxia-inducible factor-1{alpha}) and the antiangiogenic factor (thrombospondin-1) were upregulated in cortical tubular cells of the DOCA group during the 2 phases and only in the delayed phase, respectively. In the DOCA group, PTC endothelial cell apoptosis was enhanced during the 2 phases, and PTC endothelial cell proliferation was inhibited in the delayed phase. In accordance with upregulation of thrombospondin-1, p53 expression was enhanced in the DOCA group in the delayed phase. The initial and delayed effects of DOCA were blocked in the spironolactone group. We conclude that exposure to DOCA initially caused the reduced PTC density associated with enhanced apoptosis independent of thrombospondin-1, which induced tubulointerstitial fibrosis via p53-mediated thrombospondin-1 activation, and spironolactone conversely corrected the effects of DOCA to prevent fibrosis.


Key words: tubular hypoxia • peritubular capillary • endothelial cell apoptosis • thrombospondin-1 • p53